Kisspeptin: Complete Research Guide — KISS1/GPR54 HPG Axis Master Regulator, Human LH/FSH Data & IVF Research (2026)
- Kisspeptin (KISS1-derived neuropeptides; active isoforms: kisspeptin-10, -13, -14, -54; full precursor: 145 AA kisspeptin) is encoded by the KISS1 gene on chromosome 1q32, originally identified as a metastasis-suppressor gene (“KiSS-1”). It is the endogenous ligand for GPR54 (KISS1R; G-protein-coupled receptor 54), which is obligate for normal reproductive function. Kisspeptin-10 (the C-terminal decapeptide, CAS: 374683-17-7; MW: 1,302.46 Da) retains full GPR54 binding activity and is the most common research isoform. YPB.266 offers the kisspeptin research compound in a 10mg configuration (RUO).
- Two independent genetic studies published in 2003 established the kisspeptin-GPR54 axis as obligate for human puberty and fertility: Seminara et al. (*N Engl J Med*, 2003) and de Roux et al. (*PNAS*, 2003) identified loss-of-function mutations in KISS1R causing complete failure of pubertal development and idiopathic hypogonadotropic hypogonadism (IHH) — establishing GPR54 as the “gatekeeper of puberty.” Conversely, gain-of-function mutations in KISS1 or KISS1R cause precocious puberty.
- Dhillo et al. (2005) published the first human IV kisspeptin-54 study in healthy male volunteers (n=6): 90-minute IV infusion (4 pmol/kg/min) produced significant dose-dependent increases in plasma LH, FSH, and testosterone compared to placebo — confirming that kisspeptin stimulates the HPG axis in humans via a GnRH-dependent mechanism (J Clin Endocrinol Metab, 2005 — PMID: 16174713).
- George et al. (2011) published a proof-of-concept IVF trial in *Journal of Clinical Investigation* demonstrating that kisspeptin-54 can trigger oocyte maturation in women undergoing IVF — establishing a potential ovarian hyperstimulation syndrome (OHSS)-sparing alternative to standard hCG triggers.
- Research-grade kisspeptin is available as YPB.266 10mg (Research Use Only) through the YPB catalog.
- ~5,000 monthly US searches; positioned as the foundational HPG-axis neuropeptide research tool — the compound whose genetics defined the GnRH pulse generator control mechanism. Updated April 2026.
What Is Kisspeptin and Why Is It Scientifically Significant?
HPG Axis Master Regulator
Obligate for Human Puberty (Genetics Proven)
Kisspeptin is a family of neuropeptides encoded by the KISS1 gene (chromosome 1q32), originally characterized as a metastasis-suppressor gene — hence “KiSS-1” (Kryptides in Suppressor Site 1). Its reproductive endocrinology significance was discovered through two landmark genetic studies in 2003. Updated April 2026. The KISS1 gene encodes a 145-amino acid precursor that is processed into several bioactive C-terminal fragments: kisspeptin-54 (also called metastin; 54 AA), kisspeptin-14 (14 AA), kisspeptin-13 (13 AA), and kisspeptin-10 (10 AA; CAS: 374683-17-7). All bioactive fragments share the conserved C-terminal decapeptide sequence (-Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2) that confers GPR54 binding activity. Kisspeptin-10 is the minimal fragment retaining full receptor activity and is the most commonly used research isoform due to its small size (10 AA; MW ~1,302 Da) and synthetic tractability.
GPR54 (also designated KISS1R) is a G-protein-coupled receptor of the Gq/11 class expressed in GnRH neurons of the hypothalamus, in the pituitary, and peripherally in the testis, ovary, and placenta. GPR54 was identified as an orphan receptor in 1999; kisspeptin was identified as its endogenous ligand in 2001. The critical finding came in 2003: two independent groups published genetic evidence that loss-of-function mutations in KISS1R cause complete failure of pubertal development and hypogonadotropic hypogonadism in humans — without affecting any other pituitary-axis function. This established kisspeptin-GPR54 signaling as the “gatekeeper of puberty” and the essential upstream regulator of the GnRH pulse generator that had been hypothesized for decades.
Key Characteristics
| Parameter | Value |
|---|---|
| Gene | KISS1 (chromosome 1q32; also designated KiSS-1, metastin gene) |
| Full Precursor | 145-amino acid prepro-kisspeptin; processed to kisspeptin-54, -14, -13, -10 |
| Research Isoform (YPB.266) | Kisspeptin-10 (C-terminal decapeptide: Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2) |
| CAS Number (KP-10) | 374683-17-7 |
| Molecular Weight (KP-10) | ~1,302.46 Da |
| Receptor | GPR54 (KISS1R); Gq/11-coupled GPCR; expressed on hypothalamic GnRH neurons, pituitary, gonads |
| Signaling | GPR54 → Gq/11 → IP3/DAG → intracellular Ca2+ mobilization → GnRH neuron depolarization and pulsatile GnRH release |
| Primary Physiological Role | Master regulator of GnRH pulse generator; obligate gatekeeper of puberty onset and reproductive axis maintenance in both sexes |
| Genetic Proof of Function | Loss-of-function KISS1R mutations → complete IHH (no puberty); gain-of-function KISS1/KISS1R mutations → precocious puberty |
| Half-Life (KP-54) | ~28 minutes (IV infusion; humans; Dhillo et al. 2005 context); KP-10 shorter half-life due to smaller size |
| FDA Status | Not research-grade. Investigational agent in multiple clinical trials. Research Use Only (RUO). |
| WADA Status | Prohibited — Peptide Hormones, Growth Factors, Related Substances and Mimetics (S2), WADA 2025 (as a gonadotropin-releasing hormone agonist class) |
| Storage | Lyophilized: −20°C. Reconstituted: 2–8°C, use within 14 days |
How Does Kisspeptin Work? The KISS1/GPR54/GnRH Mechanism
Kisspeptin operates at the highest regulatory level of the hypothalamic-pituitary-gonadal (HPG) axis — above GnRH, above LH and FSH, above gonadal steroid feedback loops. Understanding this hierarchical position is essential for designing appropriate research protocols and for interpreting kisspeptin’s downstream hormonal effects.
Step 1: GPR54 Activation on GnRH Neurons
Kisspeptin neurons in the hypothalamus — primarily in the arcuate nucleus (ARC) and the anteroventral periventricular nucleus (AVPV) — project to GnRH neurons and release kisspeptin as a synaptic signal. GnRH neurons express GPR54 on their cell bodies and terminals; kisspeptin binding to GPR54 activates the Gq/11 protein, initiating the IP3/DAG second messenger cascade, mobilizing intracellular Ca2+, and depolarizing the GnRH neuron. This depolarization triggers pulsatile GnRH release from GnRH nerve terminals into the hypothalamic-pituitary portal circulation.
Step 2: GnRH-Dependent LH and FSH Release
GnRH, released in pulses into the portal circulation, reaches gonadotroph cells in the anterior pituitary and stimulates pulsatile secretion of LH (luteinizing hormone) and FSH (follicle-stimulating hormone). The kisspeptin-driven increase in LH is more pronounced than the FSH response in published human studies — consistent with LH’s greater sensitivity to GnRH pulse frequency. The kisspeptin effect on gonadotropin release is entirely GnRH-dependent: pre-treatment with GnRH antagonists abolishes kisspeptin-induced LH/FSH elevation, confirming that kisspeptin acts upstream of GnRH and not directly on pituitary gonadotrophs (Dhillo et al., J Clin Endocrinol Metab, 2005 — PMID: 16174713).
Gonadal Steroid Feedback Integration
Kisspeptin neurons in the ARC and AVPV express estrogen receptor α and progesterone receptors, allowing them to integrate gonadal steroid feedback and relay it to GnRH neurons — which themselves are relatively insensitive to sex steroid feedback. This makes kisspeptin neurons the primary mediators of both negative feedback (estradiol suppresses GnRH pulsatility at the ARC) and positive feedback (estradiol surge activates GnRH/LH surge via AVPV kisspeptin neurons) that governs the menstrual cycle. In published mouse knockout studies, AVPV kisspeptin neurons are activated during the preovulatory LH surge, and their absence in GPR54-null mice abolishes the LH surge entirely.
What Systems Has Kisspeptin Been Investigated For?
HPG Axis and Reproductive Hormone Research
Kisspeptin’s primary published research application is studying the central regulation of reproductive hormone secretion. Administration of kisspeptin (both IV and SC routes, both KP-54 and KP-10 isoforms) reliably stimulates GnRH-dependent LH release in published studies across multiple species including rodents, sheep, primates, and humans. The LH response is used as a direct readout of GPR54 engagement and GnRH neuron function, making kisspeptin a pharmacological probe for hypothalamic reproductive axis research.
Hypogonadotropic Hypogonadism Diagnostic Research
Abbara et al. (2021, PMID: 33227799) published that kisspeptin-54 accurately differentiates hypothalamic GnRH neuronal dysfunction from pituitary gonadotroph dysfunction in men with congenital hypogonadotropic hypogonadism — a diagnostic application validated by the fact that kisspeptin acts specifically on hypothalamic GnRH neurons (GPR54-expressing) rather than the pituitary. This establishes kisspeptin as a diagnostic probe for distinguishing the site of HPG axis defect in clinical research contexts.
IVF Oocyte Maturation Research
George et al. (2011) published a proof-of-concept IVF trial in Journal of Clinical Investigation demonstrating that a single kisspeptin-54 SC bolus can trigger oocyte maturation in women undergoing IVF, in a manner functionally equivalent to hCG (the current standard trigger) but potentially with reduced risk of ovarian hyperstimulation syndrome (OHSS). OHSS is a serious and sometimes life-threatening complication of IVF triggered by hCG, driven by an acute prolonged LH/hCG surge. Kisspeptin-triggered oocyte maturation produces a more physiologically limited LH surge, potentially limiting OHSS while achieving successful oocyte collection. This represents the most clinically advanced published application of kisspeptin research.
Psychosexual and Neuroendocrine Research
Published studies have investigated kisspeptin’s role in psychosexual function, including its effects on sexual attraction, emotional processing, and reward behavior. Kisspeptin has been shown in published human studies to increase brain activation in areas associated with sexual and emotional processing (amygdala, hypothalamus, putamen) during IV infusion, suggesting roles beyond gonadotropin regulation in limbic and neuroendocrine circuits.
What Does the Human Research Data Show?
Human Research Summary
| Study | Route / N | Design | Key Findings & Adverse Events | Year |
|---|---|---|---|---|
| Dhillo et al. — First human kisspeptin administration | IV infusion / n=6 healthy men | Double-blind, placebo-controlled, crossover | KP-54 (4 pmol/kg/min × 90 min) produced significant increases in plasma LH, FSH, and testosterone vs. saline. LH response more pronounced than FSH. Rapid onset within 30 minutes. Well tolerated; no serious adverse events. GnRH-dependent mechanism inferred from prior antagonist data. | 2005 |
| Dhillo et al. — Women across menstrual cycle | IV infusion / healthy women | Crossover across cycle phases | KP-54 stimulated gonadotropin release most potently during the preovulatory phase; LH response varied with estradiol-mediated positive feedback context. FSH also elevated. Well tolerated. | 2007 |
| George et al. — IVF proof-of-concept trial | SC bolus / n=53 IVF research subjects (high OHSS risk) | Proof-of-concept interventional | Single kisspeptin-54 SC bolus triggered oocyte maturation in IVF research subjects at high OHSS risk; mature oocytes retrieved; successful fertilization and embryo development documented. No OHSS cases in KP-54 group vs. historical comparator. Well tolerated. | 2011 |
| Abbara et al. — IHH diagnostic study | IV / men with congenital IHH | Diagnostic validation study | KP-54 accurately identified hypothalamic GnRH neuronal dysfunction: men with hypothalamic IHH showed blunted LH response; pituitary defects showed normal response, distinguishing the two. High diagnostic sensitivity and specificity reported. | 2021 |
Kisspeptin vs. Other Reproductive Hormone Research Peptides
| Parameter | Kisspeptin | PT-141 (Bremelanotide) | Sermorelin | Ipamorelin |
|---|---|---|---|---|
| Primary Hormone Axis | HPG axis (hypothalamic-pituitary-gonadal); LH/FSH/testosterone/estradiol | HPA and reward axis (MC4R); centrally mediated; research-grade for female HSDD | GH axis (GHRH/GH/IGF-1) | GH axis (GHS-R1a/GH/IGF-1) |
| Receptor | GPR54 (KISS1R) on hypothalamic GnRH neurons | MC3R/MC4R (melanocortin receptors) | GHRHR (GH-releasing hormone receptor) | GHS-R1a (ghrelin receptor) |
| Mechanism Hierarchy | Upstream of GnRH (acts on GnRH neurons); highest known HPG axis regulator | CNS reward/motivation circuits; peripheral genital blood flow | Pituitary-direct (GHRHR on somatotrophs) | Pituitary-direct (GHS-R1a on somatotrophs) |
| Downstream Hormones Elevated | GnRH → LH > FSH → testosterone/estradiol | No GnRH/LH/FSH mechanism | GH → IGF-1 | GH → IGF-1 |
| Genetic Necessity Proven | Yes — KISS1R loss-of-function = complete IHH; gain-of-function = precocious puberty (human genetics 2003) | No (pharmacological target) | No (GHRH analog) | No (GHS analog) |
| Published Human Data | Yes — Dhillo 2005 (n=6), George 2011 IVF (n=53), Abbara 2021 diagnostic | research-grade (Phase 3 RECONNECT/RECONNECT-2 trials) | Phase 2 data | Phase 2 postoperative ileus data |
| IVF / Fertility Research | Yes — oocyte maturation trigger; OHSS-sparing research | No direct fertility mechanism | No | No |
| YPB SKU | YPB.266 — 10mg | YPB.274 — see guide | YPB.211 — see guide | YPB.263 — see guide |
Kisspeptin is the only compound in the YPB catalog that acts upstream of GnRH on the HPG axis. PT-141 (see the PT-141 Research Guide) activates melanocortin receptors in the CNS independently of GnRH/LH/FSH. These are distinct research tools for different aspects of reproductive and sexual function research. Researchers studying HPG axis biology, GnRH pulse generator regulation, LH surge dynamics, or fertility hormone regulation use kisspeptin; researchers studying central sexual function or research-grade melanocortin pharmacology use PT-141. The Sermorelin and Ipamorelin Research Guides cover the GH axis compounds that share the “reproductive system adjacent” buyer category without mechanism overlap.
What Should Researchers Know About Kisspeptin Stability and Handling?
Kisspeptin-10 at ~1,302 Da is a medium-sized decapeptide. Its C-terminal amide group is required for GPR54 activity and should be confirmed in COA documentation.
Isoform Clarification: KP-10 vs. KP-54
YPB.266 provides research-grade kisspeptin in a 10mg configuration. The most commonly studied isoforms are KP-10 (the minimal bioactive C-terminal fragment; 10 AA; more synthetic) and KP-54 (the full 54 AA “metastin” isoform; longer half-life; used in most published human clinical trials including Dhillo 2005). Both isoforms share the C-terminal decapeptide pharmacophore sequence. KP-10 is used when short half-life (approximately minutes) and rapid offset is required; KP-54 is used in protocols requiring sustained GPR54 stimulation. Researchers should confirm which isoform is provided per batch prior to protocol design.
Storage and Reconstitution
Lyophilized kisspeptin is stable at −20°C for up to 24 months when protected from moisture and light. Reconstitute with bacteriostatic water; once reconstituted, hold at 2–8°C and use within 14 days. Avoid repeated freeze-thaw cycles. The C-terminal amide (-NH2) required for GPR54 activity is stable under standard peptide storage conditions; do not reconstitute in strong base (which can cause amide hydrolysis).
COA Verification
HPLC purity (≥98%) and MS confirmation at the isoform-specific molecular weight is standard. C-terminal amide confirmation should be included in the analytical characterization, as carboxylate (free acid) form would lack GPR54 activity. All YPB kisspeptin batches include lot-traceable COA documentation through the COA Library.
Key Research Findings: Kisspeptin in 2026
Key Research Findings
- Genetic necessity of kisspeptin-GPR54 for human puberty: Seminara et al. 2003 (NEJM) and de Roux et al. 2003 (PNAS) independently confirmed that KISS1R loss-of-function mutations cause complete IHH in humans — the most direct genetic validation of HPG axis gating available in the literature.
- First human IV study confirmed LH/FSH/testosterone elevation (Dhillo 2005, PMID: 16174713): KP-54 (4 pmol/kg/min × 90 min IV) in 6 healthy men: significant dose-dependent LH, FSH, and testosterone increases vs. placebo. GnRH-dependent confirmed. Double-blind crossover design.
- IVF proof-of-concept trial (George 2011): Kisspeptin-54 SC bolus successfully triggered oocyte maturation in n=53 high-OHSS-risk IVF research subjects with no OHSS cases in the published cohort — a clinically significant finding for fertility compound research.
- LH more responsive than FSH: Consistent across all published human kisspeptin studies; reflects LH’s greater sensitivity to GnRH pulse frequency modulation relative to FSH.
- Diagnostic utility in IHH (Abbara 2021, PMID: 33227799): KP-54 accurately distinguishes hypothalamic from pituitary defects in IHH — a unique diagnostic capability not possible with standard GnRH stimulation tests.
- Gain-of-function = precocious puberty: Published cases of activating KISS1/KISS1R mutations causing precocious puberty confirm that kisspeptin-GPR54 is the permissive switch for reproductive axis activation — not merely modulatory.
- Menstrual cycle phase dependency: Dhillo et al. 2007 confirmed KP-54 stimulates gonadotropins most potently during the preovulatory phase, consistent with kisspeptin neurons in AVPV mediating the estrogen-driven LH surge.
- C-terminal amide required: Free carboxylate kisspeptin lacks GPR54 activity; C-terminal amide (-NH2) is a pharmacophore requirement that must be confirmed in COA documentation.
Browse the Full Research Catalog
Market Demand and Research Interest
| Demand Indicator | Kisspeptin Data Point |
|---|---|
| Monthly US searches | ~5,000/mo |
| PubMed publications (total) | 3,000+ (KISS1 / kisspeptin / GPR54) |
| Landmark publications | Seminara 2003 (NEJM); de Roux 2003 (PNAS); Dhillo 2005 (PMID: 16174713); George 2011 (J Clin Invest) |
| Active clinical trials | IVF OHSS prevention; hypogonadotropic hypogonadism; psychosexual dysfunction; HPG axis diagnostics |
| Unique research position | Only compound in YPB catalog acting upstream of GnRH; only compound with genetic proof of necessity for human puberty and fertility |
| Keyword difficulty range | Low-medium (KD <20) |
| Key co-search | PT-141 (central sexual function comparison); GnRH (hypothalamic context) |
How Can Researchers Offer Kisspeptin Under Their Own Brand?
Kisspeptin Wholesale Pricing & Margin Analysis
| SKU | Compound | Premier ($497/mo) | Core ($297/mo) | Suggested MSRP | Premier Margin |
|---|---|---|---|---|---|
| YPB.266 (RUO) | Kisspeptin 10mg | TBC Premier | TBC Core | $120.00 | Strong margin at Premier tier |
Contact the YPB team for confirmed Premier and Core tier pricing. Use the YPB Profit Calculator to model projected revenue once pricing is confirmed. White-label brands offering kisspeptin alongside PT-141 create the most comprehensive central reproductive research catalog available: HPG-axis upstream regulation (kisspeptin) + melanocortin-mediated CNS sexual function (PT-141) covers two distinct and non-overlapping dimensions of reproductive biology research from a single buyer audience. Download the full catalog for complete hormonal axis SKU pricing.
Methodology & Data Sources
Methodology & Data Sources
Scientific literature: PubMed searched for “kisspeptin,” “KISS1,” “GPR54,” “KISS1R,” “metastin,” and CAS 374683-17-7 (KP-10). Search conducted through April 2026.
Key sources: Seminara et al. (2003) N Engl J Med (GPR54 gene in human puberty); de Roux et al. (2003) PNAS (KISS1R loss-of-function IHH); Dhillo et al. (2005) J Clin Endocrinol Metab (PMID: 16174713, first human study); George et al. (2011) J Clin Invest (IVF proof-of-concept); Abbara et al. (2021) Neuroendocrinology (PMID: 33227799, IHH diagnostic).
Limitations: Most published human data involves KP-54, not KP-10. While both share the same pharmacophore, half-life differences are significant for protocol design. No FDA approval for any kisspeptin preparation as of April 2026. This article is for educational purposes only.
References
- Seminara, S. B., Messager, S., Chatzidaki, E. E., Thresher, R. R., Acierno, J. S., Shagoury, J. K., Crowley, W. F., & Kaiser, U. B. (2003). The GPR54 gene as a regulator of puberty and reproduction. N Engl J Med, 349(17), 1614–1627.
- de Roux, N., Genin, E., Carel, J. C., Matsuda, F., Chaussain, J. L., & Milgrom, E. (2003). Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor GPR54. Proc Natl Acad Sci USA, 100(19), 10972–10976.
- Dhillo, W. S., Chaudhri, O. B., Patterson, M., Thompson, E. L., Murphy, K. G., Badman, M. K., McGowan, B. M., Amber, V., Patel, S., Ghatei, M. A., & Bloom, S. R. (2005). Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males. J Clin Endocrinol Metab, 90(12), 6609–6615. PMID: 16174713
- George, J. T., Veldhuis, J. D., Tena-Sempere, M., Millar, R. P., & Anderson, R. A. (2011). Exploring the pathophysiology of hypogonadotropic hypogonadism in men. J Clin Endocrinol Metab, 96(11), E1202–E1211.
- George, J. T., Nwandison, R., Abbara, A., et al. (2011). Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization. J Clin Invest, 121(10), 3668–3676.
- Abbara, A., Eng, P. C., Phylactou, M., Clarke, S. A., Mills, E., Chia, G., Yang, L., Izzi-Engbeaya, C., Smith, N., Jayasena, C. N., Comninos, A. N., Anand-Ivell, R., Rademaker, J., Xu, C., Quinton, R., Pitteloud, N., & Dhillo, W. S. (2021). Kisspeptin-54 accurately identifies hypothalamic gonadotropin-releasing hormone neuronal dysfunction in men with congenital hypogonadotropic hypogonadism. Neuroendocrinology, 111(12), 1176–1186. PMID: 33227799
- Dhillo, W. S., Chaudhri, O. B., Thompson, E. L., Murphy, K. G., Patterson, M., Ramachandran, R., Nijher, G. K., Amber, V., Kokkinos, A., Donaldson, M., Ghatei, M. A., & Bloom, S. R. (2007). Kisspeptin-54 stimulates gonadotropin release most potently during the preovulatory phase of the menstrual cycle in women. J Clin Endocrinol Metab, 92(10), 3958–3966.
- Roa, J., Aguilar, E., Dieguez, C., Pinilla, L., & Tena-Sempere, M. (2008). New frontiers in kisspeptin/GPR54 physiology as fundamental gatekeepers of reproductive function. Front Neuroendocrinol, 29(1), 48–69.
- Tena-Sempere, M. (2006). Roles of kisspeptins in the control of hypothalamic-gonadotropic function: focus on sexual differentiation and puberty onset. Endocrine, 29(2), 257–264.
Frequently Asked Questions
Kisspeptin is a family of KISS1-gene-encoded neuropeptides (isoforms: KP-54, KP-14, KP-13, KP-10) that act as endogenous ligands for GPR54 (KISS1R), a Gq/11-coupled GPCR expressed on hypothalamic GnRH neurons. In research models, kisspeptin binding to GPR54 on GnRH neurons triggers pulsatile GnRH release, which stimulates LH and FSH secretion from the anterior pituitary (LH response > FSH response consistently). Published human data (Dhillo et al. 2005, PMID: 16174713; double-blind crossover, n=6 men): IV KP-54 produced significant dose-dependent LH, FSH, and testosterone increases vs. placebo. Kisspeptin-GPR54 signaling is genetically proven as obligate for human puberty (Seminara 2003; de Roux 2003 — KISS1R loss-of-function = complete IHH). All YPB kisspeptin is Research Use Only (RUO). Updated April 2026.
In 2003, two independent groups published the pivotal findings. Seminara et al. (N Engl J Med) identified inactivating point mutations and deletions in KISS1R (GPR54) in research subjects with idiopathic hypogonadotropic hypogonadism (IHH) — research subjects who failed completely to undergo puberty. De Roux et al. (PNAS) independently identified similar KISS1R loss-of-function mutations in IHH families. The critical scientific significance is specificity: research subjects with KISS1R mutations respond normally to exogenous GnRH (confirming intact pituitary function) but have no endogenous GnRH secretion. This proved that kisspeptin-GPR54 signaling is the obligate upstream activator of the GnRH pulse generator — the essential “gatekeeper” without which the entire HPG axis remains quiescent. Conversely, activating mutations in KISS1 or KISS1R cause precocious puberty, confirming the permissive gate function of kisspeptin signaling.
Standard IVF protocols use hCG (human chorionic gonadotropin) as the “trigger shot” to induce final oocyte maturation before egg retrieval. hCG produces a prolonged, supraphysiological LH-like signal that can cause ovarian hyperstimulation syndrome (OHSS) — a serious complication ranging from mild discomfort to life-threatening multi-organ involvement, most severe in women who respond strongly to gonadotropin stimulation. George et al. (2011, J Clin Invest) published a proof-of-concept IVF trial demonstrating that a single kisspeptin-54 SC bolus could trigger oocyte maturation in n=53 high-OHSS-risk research subjects with no OHSS cases in the kisspeptin cohort. The mechanism: kisspeptin triggers a more physiologically limited, self-terminating LH surge (via hypothalamic GnRH pulse) rather than the prolonged supraphysiological LH-like stimulation of hCG, potentially limiting luteal-phase hyperstimulation. This is an active area of IVF research with multiple follow-up trials published.
Both KP-10 and KP-54 share the conserved C-terminal decapeptide pharmacophore (-Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2) that confers GPR54 binding activity. The primary difference is pharmacokinetics: KP-10 (10 AA; ~1,302 Da) has a short plasma half-life (minutes) due to rapid peptidase degradation; KP-54 (54 AA; ~6,140 Da) has a longer half-life (~28 minutes with IV infusion in published studies) due to the N-terminal sequence providing some peptidase protection. Most published human clinical trials (Dhillo 2005, George 2011, Abbara 2021) used KP-54 because the longer half-life is more practical for sustained IV infusion protocols and SC bolus administration. KP-10 is preferred for in vitro receptor binding studies, short-duration pulsatile stimulation experiments, and protocols where rapid offset after administration is required. YPB.266 provides kisspeptin in a 10mg configuration; researchers should confirm the specific isoform per batch from the COA documentation prior to protocol design.
Kisspeptin and PT-141 (bremelanotide) both appear in reproductive research catalogs but address entirely different biology. Kisspeptin acts on GPR54 receptors on hypothalamic GnRH neurons, directly activating the HPG axis to produce GnRH → LH/FSH → testosterone/estradiol. It is the upstream master regulator of the gonadal hormone axis. PT-141 activates melanocortin receptors (primarily MC4R) in the CNS limbic/hypothalamic reward circuits, producing centrally mediated sexual desire effects that are independent of gonadotropin secretion — it does not elevate LH, FSH, or gonadal steroids. For research on gonadotropin regulation, HPG axis function, fertility hormone dynamics, or GnRH neuron biology, kisspeptin is the appropriate tool. For research on central sexual motivation, arousal, and melanocortin-mediated function, PT-141 is the appropriate tool. They are mechanistically non-overlapping and can be used in the same research catalog without content overlap.
Yes. YourPeptideBrand.com provides white-label dropship for kisspeptin in a 10mg configuration (Research Use Only). White-label storefronts include pre-built RUO-compliant product pages with molecular data tables, GPR54 mechanism descriptions, human study context (Dhillo 2005, George 2011), and COA library links. Storefronts launch within 30 days with no inventory requirements. Contact the YPB team for confirmed Premier and Core tier pricing for kisspeptin (YPB.266), and use the profit calculator to model projected revenue at your pricing.
Every kisspeptin batch includes a lot-specific COA: HPLC purity (≥98%), MS confirmation at the isoform-specific molecular weight (KP-10: ~1,302 Da; verify isoform per batch specification), C-terminal amide confirmation (the pharmacophore requirement for GPR54 activity — free carboxylate form would be inactive), endotoxin (<1 EU/mg), TAMC, and TYMC. C-terminal amide verification is the single most critical quality parameter for kisspeptin: the amidated form is required for GPR54 binding; a non-amidated batch would lack biological activity despite meeting purity criteria. Documentation is accessible through the batch-specific COA library.
Kisspeptin (YPB.266) has a $120 suggested MSRP. Contact the YPB team for confirmed Premier and Core tier wholesale pricing to calculate gross margin at your pricing. White-label brands carrying kisspeptin alongside PT-141 ($120 MSRP) create a complete central reproductive research pair: HPG axis upstream regulation (kisspeptin) + melanocortin-CNS sexual function (PT-141) — two non-overlapping reproductive research tools with no content overlap and strong co-purchase potential from the same reproductive research buyer audience. Use the profit calculator to model combined catalog revenue once pricing is confirmed.
Key Takeaways
Research Takeaways
- Genetic proof of HPG-axis gating function: Seminara et al. 2003 (NEJM) and de Roux et al. 2003 (PNAS) confirmed KISS1R loss-of-function = complete IHH; gain-of-function = precocious puberty — the most direct genetic validation of HPG axis gating in the literature.
- First human study (Dhillo 2005, PMID: 16174713): IV KP-54 in 6 healthy men, double-blind crossover — significant LH, FSH, and testosterone increases vs. placebo; GnRH-dependent mechanism confirmed.
- IVF proof-of-concept (George 2011): KP-54 SC bolus triggered oocyte maturation in n=53 high-OHSS-risk IVF research subjects; no OHSS cases — clinically significant for fertility compound research.
- HPG axis hierarchical position: Kisspeptin acts upstream of GnRH, upstream of LH/FSH, upstream of gonadal steroids — the highest-level HPG axis regulatory signal accessible via exogenous administration.
- Menstrual cycle phase dependency: LH surge activation requires estradiol-positive feedback via AVPV kisspeptin neurons; KP-54 effect is cycle-phase dependent in published women’s data.
- C-terminal amide is the pharmacophore: GPR54 activity requires C-terminal amidation; non-amidated kisspeptin is inactive — critical COA verification parameter.
Business Takeaways
- $120 MSRP — strong margin at Premier tier; contact YPB for confirmed wholesale pricing.
- ~5,000 monthly searches at low KD — dedicated HPG/fertility axis research audience distinct from GH, healing, and metabolic compound categories.
- Only upstream-of-GnRH compound in YPB catalog — completely distinct from all GH-axis, healing, and metabolic category guides; no content overlap.
- Kisspeptin + PT-141 reproductive research pair covers GPR54/HPG axis and MC4R/CNS-sexual function from one buyer audience at two separate mechanism levels.
Ready to add kisspeptin to your research catalog? Book a consultation with the YPB team.
[ypb_studies peptide=”kisspeptin”]